M
Monika Brüggemann
Researcher at University of Kiel
Publications - 198
Citations - 17026
Monika Brüggemann is an academic researcher from University of Kiel. The author has contributed to research in topics: Minimal residual disease & Medicine. The author has an hindex of 48, co-authored 154 publications receiving 14255 citations. Previous affiliations of Monika Brüggemann include Charité & Keil.
Papers
More filters
Journal ArticleDOI
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.
J. J. M. Van Dongen,Anthonie Willem Langerak,Monika Brüggemann,Paul Evans,Michael Hummel,F. L. Lavender,Eric Delabesse,Frederic Davi,Ed Schuuring,Ramón García-Sanz,J.H.J.M. van Krieken,J Droese,David Gonzalez,Christian Bastard,Helen E. White,Marcel Spaargaren,Marcos González,A Parreira,John L. Smith,Gareth J. Morgan,Michael Kneba,Elisabeth Macintyre +21 more
TL;DR: The BIOMED-2 multiplex tubes can now be used for diagnostic clonality studies as well as for the identification of PCR targets suitable for the detection of minimal residual disease.
Journal ArticleDOI
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop M. Kantarjian,Anthony S. Stein,Nicola Gökbuget,Adele K. Fielding,Andre C. Schuh,Josep-Maria Ribera,Andrew H. Wei,Hervé Dombret,Robin Foà,Renato Bassan,Onder Arslan,Miguel A. Sanz,Julie Bergeron,Fatih Demirkan,Ewa Lech-Maranda,Alessandro Rambaldi,Xavier Thomas,Heinz-August Horst,Monika Brüggemann,Wolfram Klapper,Brent L. Wood,Alex Fleishman,Dirk Nagorsen,Chris Holland,Zachary Zimmerman,Max S. Topp +25 more
TL;DR: Treatment with blinatumomab resulted in significantly longer overall survival than chemotherapy among adult patients with relapsed or refractory B‐cell precursor ALL, and remission rates within 12 weeks after treatment initiation were significantly higher.
Journal ArticleDOI
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Max S. Topp,Nicola Gökbuget,Anthony S. Stein,Gerhard Zugmaier,Susan O'Brien,Ralf C. Bargou,Hervé Dombret,Adele K. Fielding,Leonard T. Heffner,Richard A. Larson,Svenja Neumann,Robin Foà,Mark R. Litzow,Josep-Maria Ribera,Alessandro Rambaldi,Gary J. Schiller,Monika Brüggemann,Heinz A. Horst,Chris Holland,Catherine Jia,Tapan Maniar,Birgit Huber,Dirk Nagorsen,Stephen J. Forman,Hagop M. Kantarjian +24 more
TL;DR: Single-agent blinatumomab showed antileukaemia activity in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia characterised by negative prognostic factors.
Journal ArticleDOI
Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp,Peter Kufer,Nicola Gökbuget,Mariele Goebeler,Matthias Klinger,Svenja Neumann,Heinz-A. Horst,Thorsten Raff,Andreas Viardot,Mathias Schmid,Matthias Stelljes,Markus Schaich,Evelyn Degenhard,Rudolf Köhne-Volland,Monika Brüggemann,Oliver G. Ottmann,Heike Pfeifer,Thomas Burmeister,Dirk Nagorsen,Margit Schmidt,Ralf Lutterbuese,Carsten Reinhardt,Patrick A. Baeuerle,Michael Kneba,Hermann Einsele,Gert Riethmüller,Dieter Hoelzer,Gerhard Zugmaier,Ralf C. Bargou +28 more
TL;DR: T cells engaged by blinatumomab seem capable of eradicating chemotherapy-resistant tumor cells that otherwise cause clinical relapse in patients with MRD-positive B-lineage ALL after intensive chemotherapy.
Journal ArticleDOI
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.
J. J. M. Van Dongen,Ludovic Lhermitte,S Böttcher,Julia Almeida,V H J van der Velden,Juan Flores-Montero,Andy C. Rawstron,Vahid Asnafi,Quentin Lecrevisse,Paulo Sérgio Lucio,Ester Mejstrikova,Tomasz Szczepański,Tomas Kalina,R de Tute,Monika Brüggemann,Lukasz Sedek,M Cullen,Anthonie Willem Langerak,Alexandre de Mendonça,Elizabeth Macintyre,Marta Martin-Ayuso,Ondrej Hrusak,M B Vidriales,Alberto Orfao +23 more
TL;DR: The EuroFlow studies resulted in validated and flexible 8-color antibody panels for multidimensional identification and characterization of normal and aberrant cells, optimally suited for immunophenotypic screening and classification of hematological malignancies.